LifeVantage Corporation filings document formal disclosures for a Nasdaq-listed health and wellness company that sells nutrigenomic supplements, skin and hair care products, energy drink mixes, and pet supplements through an independent Consultant model. Recent Form 8-K reports furnish quarterly operating results and describe revenue by region, earnings measures, capital allocation, and material corporate events.
Proxy and meeting filings cover board elections, advisory executive compensation votes, auditor ratification, incentive-plan matters, and final stockholder voting results. Other current reports address executive departures, officer appointments, board changes, transition agreements, and compensatory arrangements, alongside exhibit-based press releases tied to financial results and governance actions.
The Capital Management Corporation reported beneficial ownership of 2,064,176 shares of LifeVantage Corporation common stock, representing 16.3% of the class. The filing shows the filer has sole voting power over 2,041,176 shares and sole dispositive power over 2,064,176 shares. The statement is filed on a Schedule 13G/A for the reporting period ending September 30, 2025 and includes a signed certification that the securities are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer. Contact and registration details identify Pamela C. Simms as Compliance Officer for The Capital Management Corporation, organized in Virginia.
LifeVantage Corporation is asking shareholders to vote on four routine proposals at its annual meeting, including election of seven directors and approval of an amendment to its 2017 Long-Term Incentive Plan that would add 400,000 shares to the reserve and extend the plan term to December 5, 2031. As of the Record Date, 12,691,009 shares were outstanding. The Board reports 71,500 option shares and 811,576 restricted stock/RSU awards outstanding under the plan and states 1,152,619 shares are available assuming maximum performance or 1,460,207 shares assuming target performance. The company reports a fair market stock price of $10.68 on the Record Date and estimates potential dilution would rise from 18.5% to 21.6% if the amendment is approved. The proxy describes executive pay structure changes (more PRSUs versus RSUs), recent dividend increases totaling $2.1M, and share repurchases of $3.1M (about 0.3M shares).
Darwin Lewis, a director of Lifevantage Corp (LFVN), reported an automatic purchase of common stock under a Rule 10b5-1 trading plan. On 09/16/2025 he acquired 450 shares at a price of $10.8499 per share, bringing his total beneficial ownership to 117,217 shares. The filing states the 10b5-1 plan was adopted on February 10, 2025. The Form 4 was signed on behalf of Mr. Lewis by a power of attorney on 09/18/2025. The report lists the transaction as a non-derivative acquisition and identifies Mr. Lewis as a director of the issuer.
Lifevantage Corp (LFVN) director Michael A. Beindorff reported insider sales on 09/09/2025. The Form 4 shows two open-market dispositions: 4,125 shares sold at $11.44 and 200 shares sold at $11.35. After these transactions, the filing reports 22,858 shares held directly by Mr. Beindorff and indirect holdings that include 126 shares held by spouse as custodian for minor children, 91,413 shares held by a trust, and 5,500 shares held indirectly by spouse. The filing notes the trust is the Michael A. Beindorff Trust dated 06/14/2000, of which the reporting person and his spouse are trustees.
LifeVantage Corporation disclosed that on September 4, 2025 it issued a press release announcing its financial results for the fourth quarter and full fiscal year ended June 30, 2025. The press release is included as Exhibit 99.1 to the current report. The filing notes the furnished information is not being deemed "filed" under the Exchange Act and therefore is not subject to the liabilities of Section 18.
LifeVantage Corporation describes its direct-selling dietary supplement and personal-care business, emphasizing a nutrigenomics "activating wellness" strategy and product portfolio including Protandim4, TrueScience4 skin and hair care, AXIO4 energy drinks, Petandim4, and the patent-pending MindBody GLP-1 System42; MB Core42; MB Enhance42. The company reported approximately $220.0 million aggregate market value of common stock held by non-affiliates as of December 31, 2024 and 12,691,009 shares outstanding as of September 3, 2025. As of June 30, 2025 it employed 238 people and had ~51,000 active independent consultants (vs 49,000 in fiscal 2024). Approximately 22% of fiscal 2025 revenue was international, primarily Japan. There was no outstanding balance on the 2024 Credit Facility as of June 30, 2025; the facility matures April 12, 2027. The filing lists material risks including dependence on independent consultants, concentration on a few products, third-party manufacturing and supply-chain risks, regulatory and advertising scrutiny, cybersecurity and data-privacy obligations, potential tax or employment classification exposure for consultants, activist stockholder actions, and foreign currency and market-entry risks.
The Form 4 filed for LifeVantage Corp (LFVN) reports insider activity by CFO Carl Aure. On 08/31/2025 Mr. Aure had 14,792 and 18,886 Performance Restricted Stock Units (PRSUs) marked as acquired (codes M) that convert one-for-one into common stock when vesting criteria are met, and the filing notes those PRSUs were originally granted in 2023 and 2024. The report also reflects 718 shares purchased under the Employee Stock Purchase Plan, and a disposition of 16,610 shares sold at $13.10 per share. Following the transactions, the filing shows total beneficial ownership figures reported per line items.
Cunningham Kristen reported disposition transactions in this Form 4 filing.
Lifevantage Corp Chief Sales Officer Kristen Cunningham exercised performance restricted stock units, converting 43,902 PRSUs into common stock on August 31, 2025. To satisfy tax obligations, 21,801 shares were delivered at $13.10 per share. After these transactions she holds 138,706 common shares and 18,992 PRSUs directly.
Steven R. Fife, President and CEO and director of Lifevantage Corp (LFVN), reported insider transactions on 08/31/2025. Two tranches of previously granted performance restricted stock units converted into common stock: 90,718 shares (granted 08/24/2023) and 108,960 shares (granted 08/26/2024). Those PRSUs convert one-for-one into common shares and were reported as acquired at $0 under Rule 16 reporting codes. Separately, 98,177 shares were disposed of at a reported price of $13.10, leaving the reporting person with 761,001 and 859,178 total shares following the respective transactions as shown on the form.
Lifevantage Corp (LFVN) reporting person Alissa Neufeld recorded equity activity consisting of performance restricted stock units (PRSUs) and a disposition of common stock. The filing shows PRSUs granted in 2023 and 2024 that convert one-for-one into common stock, two grant-related transactions adding 14,498 and 18,886 shares (Transaction Code M) at $0 per share, and a sale (Transaction Code F) of 15,729 shares at $13.10 per share. After these transactions the reporting person beneficially owned 118,260 common shares.
The derivative section shows the PRSUs underlying 14,498 and 18,886 units, with post-transaction derivative beneficial ownership reported as 4,832 and 9,443 respectively. The filing states the PRSUs vest upon meeting pre-established time-based and financial performance criteria and convert into common stock on a one-for-one basis.